Literature DB >> 23812645

Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Georges Vauquelin1.   

Abstract

Bivalent ligands often display high affinity/avidity for and long residence time at their target. Thereto responsible is the synergy that emanates from the simultaneous binding of their two pharmacophores to their respective target sites. Thermodynamic cycle models permit the most complete description of the binding process, and thereto, corresponding differential equation-based simulations link the "microscopic" rate constants that govern the individual binding steps to the "macroscopic" bivalent ligand's binding properties. Present simulations of heterobivalent ligand binding led to an appreciably simpler description thereof. The thermodynamic cycle model can be split into two pathways/lanes that the bivalent ligand can solicit to reach fully bound state. Since the first binding event prompts the still free pharmacophore to stay into "forced proximity" of its target site, such lanes can be looked into by the equations that also apply to induced fit binding mechanisms. Interestingly, the simplest equations apply when bivalency goes along with a large gain in avidity. The overall bivalent ligand association and dissociation will be swifter than via each lane apart, but it is the lane that allows the fastest bidirectional "transit" between the free and the fully bound target that is chiefly solicited. The bivalent ligand's residence time is governed not only by the stability of the fully bound complex but also by the ability of freshly dissociated pharmacophores to successfully rebind. Hence, the presence of a slow-associating pharmacophore could be counterproductive. Yet, a long residence time is unfortunately also responsible for the slow attainment of binding equilibrium.

Mesh:

Substances:

Year:  2013        PMID: 23812645     DOI: 10.1007/s00210-013-0881-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  51 in total

1.  Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.

Authors:  E N Kaufman; R K Jain
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

Review 2.  Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors.

Authors:  Pierre De Meyts; Lisbeth Gauguin; Angela Manegold Svendsen; Mazen Sarhan; Louise Knudsen; Jane Nøhr; Vladislav V Kiselyov
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

3.  Analysis of mass transport-limited binding kinetics in evanescent wave biosensors.

Authors:  P Schuck; A P Minton
Journal:  Anal Biochem       Date:  1996-09-05       Impact factor: 3.365

Review 4.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

Review 5.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

6.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

Authors:  Robert A Copeland
Journal:  Expert Opin Drug Discov       Date:  2010-04       Impact factor: 6.098

7.  Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics.

Authors:  B Goldstein; M Dembo
Journal:  Biophys J       Date:  1995-04       Impact factor: 4.033

8.  The effect of cell size and receptor density on ligand--receptor reaction rate constants.

Authors:  C DeLisi
Journal:  Mol Immunol       Date:  1981-06       Impact factor: 4.407

9.  A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.

Authors:  Tod Steinfeld; Mathai Mammen; Jacqueline A M Smith; Richard D Wilson; Jeffrey R Jasper
Journal:  Mol Pharmacol       Date:  2007-05-03       Impact factor: 4.436

10.  Bitopic ligands: all-in-one orthosteric and allosteric.

Authors:  Maud Kamal; Ralf Jockers
Journal:  F1000 Biol Rep       Date:  2009-10-14
View more
  15 in total

Review 1.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

2.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 3.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

4.  Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.

Authors:  Dong Guo; Suzanne N Venhorst; Arnault Massink; Jacobus P D van Veldhoven; Georges Vauquelin; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 5.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

6.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

7.  Selective, rapid and optically switchable regulation of protein function in live mammalian cells.

Authors:  Yu-Hsuan Tsai; Sebastian Essig; John R James; Kathrin Lang; Jason W Chin
Journal:  Nat Chem       Date:  2015-05-18       Impact factor: 24.427

8.  Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.

Authors:  Juan Ramirez; Juline Poirson; Clémence Foltz; Yassmine Chebaro; Maxime Schrapp; Amandine Meyer; Anaëlle Bonetta; Anne Forster; Yves Jacob; Murielle Masson; François Deryckère; Gilles Travé
Journal:  Angew Chem Int Ed Engl       Date:  2015-05-27       Impact factor: 15.336

Review 9.  Behaviour of intrinsically disordered proteins in protein-protein complexes with an emphasis on fuzziness.

Authors:  Johan G Olsen; Kaare Teilum; Birthe B Kragelund
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

10.  Synthesis and evaluation of chloramphenicol homodimers: molecular target, antimicrobial activity, and toxicity against human cells.

Authors:  Ourania N Kostopoulou; George E Magoulas; Georgios E Papadopoulos; Athanasia Mouzaki; George P Dinos; Dionissios Papaioannou; Dimitrios L Kalpaxis
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.